Latest Breaking News On - Amed therapeutics - Page 1 : comparemela.com

CytoMed Therapeutics Limited (NASDAQ:GDTC) Sees Significant Increase in Short Interest

CytoMed Therapeutics Limited (NASDAQ:GDTC – Get Free Report) was the recipient of a large growth in short interest in April. As of April 15th, there was short interest totalling 39,400 shares, a growth of 11.6% from the March 31st total of 35,300 shares. Based on an average trading volume of 25,100 shares, the short-interest ratio […]

Cytomed therapeuticsCytomed therapeutics limitedGet free reportAmed therapeuticsMed therapeutics limitedCytomed therapeutics dailyNasdaq gdtc

Cannabis Stocks: Here s How to Maximize Your Gains Amid Sector s Strong Resurgence

Cannabis Stocks: Here s How to Maximize Your Gains Amid Sector s Strong Resurgence
investing.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investing.com Daily Mail and Mail on Sunday newspapers.

United statesCronos groupCanadian ministry of healthYork stock exchangeUs drug enforcement agencyToronto stock exchangeNew york stock exchangeEnforcement agencyShares pureAdvisorshares pure cannabisPrime alternative harvestCanadian ministryNew york stockAmed therapeuticsNorth americaToronto stock

Cannabis Stocks: Here s How to Maximize Your Gains Amid Sector s Strong Resurgence

United statesCanadian ministry of healthYork stock exchangeNew york stock exchangeToronto stock exchangeUs drug enforcement agencyCronos groupEnforcement agencyShares pureAdvisorshares pure cannabisPrime alternative harvestCanadian ministryNew york stockAmed therapeuticsNorth americaToronto stock

AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis

SHANGHAI, Feb. 19, 2024 /PRNewswire/ AffaMed Therapeutics ("AffaMed"), a biotechnology company dedicated to developing and commercializing transformative

South koreaVijay karwalOcular therapeutix incSingapore health sciences authorityAffamed therapeuticsNew drug applicationChief executive officerMainland chinaOcular therapeutixGreater chinaAmed therapeutics

AffaMed s Dextenza NDA Accepted In Singapore For Treating Ocular Inflammation And Pain

(RTTNews) - AffaMed Therapeutics said that the Singapore Health Sciences Authority has accepted its New Drug Application or NDA for Dextenza (0.4 .

South koreaSingapore health sciences authorityOcular therapeutix incMore such health newsAmed therapeuticsNew drug applicationMainland chinaAffamed therapeuticsOcular therapeutixGreater china